- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Established, Profitable and Undervalued
Global Pharmaceuticals & Biotech Established, Profitable and Undervalued
UPDATED Jul 03, 2022
Over $1bn in market cap, profitable and undervalued based on cash flows.
63 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| JNJJohnson & Johnson | US$179.52 | -1.5% | 6.2% | US$472.4b | US$187.28 | PE23.8x | E4.4% | 2.5% | ||
| PFEPfizer | US$52.31 | 1.4% | 31.7% | US$293.5b | US$57.00 | PE11.6x | E-18.0% | 3.1% | ||
| LLYEli Lilly | US$324.71 | -0.3% | 38.8% | US$292.3b | US$316.41 | PE47.7x | E20.1% | 1.2% | ||
| ROGRoche Holding | CHF320.40 | 0.5% | -8.3% | CHF262.0b | CHF386.26 | PE18.4x | E7.4% | 2.9% | ||
| ABBVAbbVie | US$153.80 | 1.0% | 33.5% | US$271.8b | US$162.17 | PE21.9x | E-0.6% | 3.7% | ||
| NOVO BNovo Nordisk | kr.784.60 | -0.2% | 47.9% | kr.1.8t | kr.813.00 | PE36.1x | E13.8% | 1.3% | ||
| MRKMerck | US$92.42 | -0.8% | 17.6% | US$233.7b | US$96.59 | PE16.8x | E11.8% | 3.0% | ||
| TMOThermo Fisher Scientific | US$548.27 | 0.6% | 6.8% | US$214.6b | US$661.95 | PE28.2x | E9.1% | 0.2% | ||
| NOVNNovartis | CHF80.33 | -0.3% | -5.0% | CHF174.5b | CHF91.19 | PE7.5x | E2.8% | 3.7% | ||
| BMYBristol-Myers Squibb | US$76.84 | -2.7% | 14.8% | US$163.6b | US$79.05 | PE26.2x | E14.0% | 2.8% | ||
| AMGNAmgen | US$245.55 | 0.3% | -1.3% | US$131.2b | US$246.51 | PE22.9x | E9.7% | 3.2% | ||
| SANSanofi | €97.52 | -3.0% | 10.9% | €121.9b | €114.78 | PE18.3x | E8.0% | 3.4% | ||
| GSKGSK | UK£17.86 | 1.7% | 24.2% | UK£90.4b | UK£18.69 | PE17.7x | E10.4% | 4.5% | ||
| CSLCSL | AU$274.80 | 0.7% | -2.6% | AU$129.7b | AU$319.21 | PE38.6x | E14.8% | 1.2% | ||
| ZTSZoetis | US$174.21 | -0.2% | -9.6% | US$82.0b | US$233.50 | PE39.6x | E11.4% | 0.7% | ||
| GILDGilead Sciences | US$62.36 | -0.7% | -10.0% | US$78.2b | US$69.65 | PE17.3x | E8.3% | 4.7% | ||
| MRKMERCK Kommanditgesellschaft auf Aktien | €165.70 | 0.5% | 1.8% | €72.0b | €210.34 | PE22.6x | E6.3% | 1.1% | ||
| VRTXVertex Pharmaceuticals | US$287.32 | 0% | 43.3% | US$73.5b | US$294.22 | PE30x | E10.3% | n/a | ||
| REGNRegeneron Pharmaceuticals | US$595.40 | -1.2% | 2.0% | US$64.2b | US$679.24 | PE8.1x | E-3.2% | n/a | ||
| BAYNBayer | €57.35 | -0.8% | 11.4% | €56.3b | €79.37 | PE25.6x | E8.7% | 3.5% | ||
| 4568Daiichi Sankyo Company | JPÂ¥3,411.00 | 2.6% | 45.4% | JPÂ¥6.5t | JPÂ¥4,135.71 | PE97.6x | E28.8% | 0.8% | ||
| 603259WuXi AppTec | CNÂ¥109.11 | 5.5% | -29.1% | CNÂ¥298.6b | CNÂ¥156.29 | PE61.6x | E22.7% | 0.5% | ||
| 4502Takeda Pharmaceutical | JPÂ¥3,812.00 | 1.0% | 2.7% | JPÂ¥5.8t | JPÂ¥4,468.13 | PE25.6x | E8.7% | 4.7% | ||
| 4519Chugai Pharmaceutical | JPÂ¥3,529.00 | -1.3% | -18.5% | JPÂ¥5.7t | JPÂ¥4,577.69 | PE15x | E0.8% | 2.2% |